Last Updated on October 19, 2024 by The Health Master
Aurobindo Pharma Ltd said on Thursday that it will make COVAXX’s C-19 vaccine candidate for India and UNICEF under a licensing deal.
The Hyderabad based drugmaker also has non-exclusive rights to sell the vaccine. The COVAXX vaccine is currently undergoing early-stage trials.
COVAXX is a unit of United Biomedical Inc and it plans to carry out mid and late-stage trials for the vaccine in Asia, Latin America and the US. The trials will begin from early 2021.
The company said that the vaccine requires ordinary refrigeration temperature and not freezing temperatures required for certain vaccines.
This bit is considered beneficial for developing countries as storage at ultra-low temperatures needs setting up of specialist cold storage chains which may prove to be a challenge in developing world.
Also read : High Court questions validity of field testing of NDPS Drugs
The licensing deal comes amid increasing C-19 cases in India.
Shares of Aurobindo Pharma rose as much as 2.3% and were trading up 1.4% as of 0403 GMT in an upbeat Mumbai market.
Aurobindo said it could currently produce 220 million doses, but is ramping up its facilities to reach a capacity of nearly 480 million by June 2021.
Its licensing deal comes as C-19 infections in India continue to rise after crossing 10 million last week. It’s the second worst-hit nation by the pandemic after the United States.
Reuters reported on Tuesday that the country is likely to approve Oxford/AstraZeneca‘s C-19 virus vaccine for emergency use by next week.
India, the world’s biggest vaccine producing country, is also considering emergency use authorization applications for vaccines made by Pfizer and local company Bharat Biotech.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
